Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,227,962
  • Shares Outstanding, K 27,688
  • Annual Sales, $ 91,280 K
  • Annual Income, $ -145,230 K
  • EBIT $ -29 M
  • EBITDA $ -37 M
  • 60-Month Beta 0.29
  • Price/Sales 13.13
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 74.19% (+5.60%)
  • Historical Volatility 63.82%
  • IV Percentile 14%
  • IV Rank 5.85%
  • IV High 297.94% on 12/06/24
  • IV Low 60.28% on 07/16/25
  • Expected Move (DTE 11) 1.80 (4.06%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 1,145
  • Put/Call OI Ratio 2.64
  • Today's Open Interest 21,481
  • Open Int (30-Day) 17,422
  • Expected Range 42.55 to 46.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.89
  • Number of Estimates 8
  • High Estimate 2.21
  • Low Estimate -0.99
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +223.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.27 +46.51%
on 11/10/25
45.32 -2.14%
on 12/04/25
+8.35 (+23.19%)
since 11/05/25
3-Month
17.11 +159.26%
on 09/16/25
45.32 -2.14%
on 12/04/25
+22.45 (+102.51%)
since 09/05/25
52-Week
12.21 +263.23%
on 02/11/25
45.32 -2.14%
on 12/04/25
+20.69 (+87.45%)
since 12/05/24

Most Recent Stories

More News
Anaptys Announces Participation in December Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 44.35 (+2.42%)
Anaptys Announces $100 Million Stock Repurchase Plan

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its...

ANAB : 44.35 (+2.42%)
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a...

ANAB : 44.35 (+2.42%)
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Rosnilimab was safe and well tolerated with similar adverse event rates vs . placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy...

ANAB : 44.35 (+2.42%)
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on...

ANAB : 44.35 (+2.42%)
Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 44.35 (+2.42%)
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy,...

ANAB : 44.35 (+2.42%)
Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB)

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on AnaptysBio. The company’s shares closed yesterday at $31.85.Elevate Your Investing Strategy: Take advantage of TipRanks...

ANAB : 44.35 (+2.42%)
Analysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT), Argenx Se (ARGX) and AnaptysBio (ANAB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Microbot Medical (MBOT – Research Report), Argenx Se (ARGX – Research Report) and AnaptysBio (ANAB –...

ANAB : 44.35 (+2.42%)
ARGX : 901.17 (-1.62%)
MBOT : 2.37 (-3.66%)
Piper Sandler Keeps Their Buy Rating on AnaptysBio (ANAB)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on AnaptysBio, with a price target of $72.00. The company’s shares closed yesterday at $32.46.Elevate Your Investing...

ANAB : 44.35 (+2.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 46.17
2nd Resistance Point 45.50
1st Resistance Point 44.93
Last Price 44.35
1st Support Level 43.69
2nd Support Level 43.02
3rd Support Level 42.45

See More

52-Week High 45.32
Last Price 44.35
Fibonacci 61.8% 32.67
Fibonacci 50% 28.76
Fibonacci 38.2% 24.86
52-Week Low 12.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar